Copyright ©
DrugPatentWatch. Originally published at
https://www.drugpatentwatch.com/blog/
![](https://www.drugpatentwatch.com/blog/wp-content/uploads/2017/10/pharmaceutical-lifecycle-management-300x200.jpg)
File this under ‘unintended consequences.’ A number of health care organizations are complaining that a final guideline the US Food and Drug Administration recently released for naming both biologic medicines and identical, but lower-cost biosimilar versions will cost the health care system billions of dollars in technology costs. How so? The guideline is designed to make…
Copyright ©
DrugPatentWatch. Originally published at